Principal Investigator
Jay Spiegel
Enrollment Status
Closed
Clinical Trial ID
Institutional Protocol #
20230774
Clinical Trial Summary
AN OPEN-LABEL, MULTICENTER PHASE 2 STUDY EVALUATING THE EFFICACY AND SAFETY OF CRG-022, A CD22-DIRECTED AUTOLOGOUS CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY IN PARTICIPANTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA AFTER CD19-DIRECTED CAR T-CELL THERAPY
Phase
Phase II
Funding Agency/Sponsor
Industrial
Disease
Lymphoma
Contact Information
Phone Number
305-243-2647